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Introduction
Several predisposing factors and microbial agents have 
been known to cause vaginitis. Vaginal infection by 
Candida spp., also known as vulvovaginal candidiasis 
(VVC), is the second most common cause of a vaginal 
infection after bacterial vaginosis (1). Among Candida 
species, Candida albicans is the most important cause 
of VVC. Epidemiological studies have revealed that C. 
glabrata is the second most usual Candida spp. after C. 
albicans (2), and ~55% of women have at least one episode 
of VVC by age 25 years (3). The prevalence of culture-
validated VVC has been reported to be ~40% in Iran (4). 
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Implication for health policy/practice/research/medical education:
Aqueous-ethanolic extract of Allium jesdianum showed promising antifungal effect against both fluconazole- susceptible and 
-resistant vaginal isolates of Candida glabrata, an important fungal pathogen. Hence, the A. jesdianum might be used to develop 
effective therapy against vaginal infections caused by C. glabrata.
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Introduction: About 50% of women are diagnosed with an episode of vulvovaginal candidiasis 
(VVC) during first 25 years of their lives. Candida glabrata is considered the second most prevalent 
non-C. albicans species associated with VVC. In this study, we examined the antifungal effect of a 
medicinal plant, Allium jesdianum, as a natural therapeutic agent against fluconazole-susceptible 
and -resistant human vaginal C. glabrata isolates, collected from two groups of volunteers; healthy 
women and women with VVC. 
Methods: An aqueous-ethanolic extract of A. jesdianum was prepared by maceration method. 
Vaginal specimens were collected from 28 women diagnosed with VVC and eight healthy subjects. 
The specimens were cultured using fungal-specific media in optimum conditions. The antifungal 
susceptibility of clinical isolates of C. glabrata to the plant extract and fluconazole was evaluated 
according to the standard protocols.
Results: Candida glabrata was found to be the major cause of vaginal infection among 15.2% of 
women with VVC. We could identify the Candida spp. yeasts that colonized the vagina of 35% of 
healthy women while 19% of the isolated yeasts strains were detected as C. glabrata. Moreover, 7.1% 
of isolates obtained from VVC-patients were fluconazole resistant. The results showed the antifungal 
effect of A. jesdianum against all fluconazole resistant and susceptible C. glabrata vaginal isolates. 
The MIC90 of aqueous-ethanol (A-EtOH) extract of A. jesdianum against C. glabrata isolates from 
both VVC-patients and healthy women was 3 mg/mL. 
Conclusion: Our results showed the promising antifungal efficacy of aqueous-ethanolic extract of 
A. jesdianum. A. jesdianum extract might be used as an alternative choice to treat the VVC infections 
caused by fluconazole resistant Candida spp.
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Most of the fungal microorganisms are classified as 
opportunistic. This implies that they can cause infections 
in the hosts with defective immune system. However, VVC 
infections are usually observed in immunocompetent 
healthy women. Over a decade ago, VVC was classified 
and now is internationally accepted and adapted. 
Umcomplicated VVC (UVVC) is characterized by mild 
to moderate symptoms in immunocompetent healthy 
women and C. albicans is often primary microbial cause of 
the infection. The disease usually can be well-controlled 
with a period of short/mid-term antifungal therapy. The 
complicated VVC (CVVC) is generally caused by non-C. 
albicans species and determined by severe symptoms. The 
CVVC is occurred among women who suffer from an 
immunosuppressing disease such as uncontrolled diabetes 
and pregnancy. A mid/long-term antifungal regimen is 
necessary for resolution of the disease (5).
In fact, ~20%-30% of healthy women experience an 
asymptomatic vaginal colonization by candida species 
in their lives (6). There is no quantitative definition for 
Candida growth in host’s body to distinguish between 
colonization and infection. However, a cut-off of 103 
to 105 CFU/mL  has been introduced by researchers to 
characterize colonization and infection. The defined 
range is equal to 1-100 Candida countable colonies on 
the culture plates. Moreover, an index named as Pittet’s 
Candida colonization index of ≤0.35 and ≥0.4 was defined 
for colonization and infection, respectively (7).
The azole resistance among non-C. albicans Candida 
species (NCC) is more frequent. In some cases, NCCs 
are acquired resistance when frequently exposed to azole 
drugs or treated with sub-lethal doses of azole antifungals. 
In a so-called acquired-resistance, C. glabrata can acquire 
rapidly resistance to azoles. The intrinsic resistance of C. 
glabrata to azoles has also been reported (2).
The antifungal effect of some novel natural-originated 
compounds has recently been investigated. These types 
of studies could help us to discover novel antifungal 
agents and extend our understanding of mechanisms of 
resistance to routine antifungals. Allium jesdianum with 
its known medicinal and antimicrobial properties has 
been used from ancient times in Iran. Typically, the plant 
grows in western and northern areas of Iran.
The aim of this study was to evaluate the antifungal effect 
of A-EtOH extract of A. jesdianum against fluconazole- 
susceptible and-resistant human vaginal C. glabrata 
isolates, collected from two groups of women; healthy 
women and women with VVC.
Materials and methods 
Plant material and preparation of herb extracts
The aerial parts of A. jesdianum which is native to Iran, 
during the flowering stage were collected from Zard-kuh 
mountains (Zagros range, Chaharmahal and Bakhtiari 
province, western part of Iran) in spring 2014. The 
plant materials were kept on ice in order to maintain 
their freshness. In the laboratory, the plant samples were 
washed with distilled water. The fresh plant including 
leaves, flowers and stems were ground using pestle and 
mortar. The ground plant material was macerated by 
mixing 5 g of the material with 250 mL of aqueous ethanol 
(A-EtOH) (ethanol: water, 70:30 v/v) for 24 hours at 
room temperature. The obtained extract was then filtered 
through Whatman no.1 filter paper, and sterilized using 
a 0.45 µm membrane filter. Afterwards, with a rotary 
evaporator at 30°C and under high vacuum, the excess 
alcohol solvent was removed. Finally, the semisolid extract 
was stored in a sterile dark glass container and kept at 
-20°C until use.
Human subjects and specimen collection
All women with VVC referred to department of obstetrics 
and gynecology of Arad hospital in Tehran, Iran were 
selected to participate (between spring and summer 2014). 
Healthy women were considered those who had attended 
at the hospital but not diagnosed with VVC, other vaginal 
infections, hormonal dysfunction, pregnancy, diabetes and 
other malignant diseases. Informed consent was obtained 
from all subjects. However, women currently receiving an 
antifungal treatment, and also women who have received 
a recent (<1 month) azole/antifungal therapy were all 
excluded from the study. All VVC-suspected subjects were 
examined by a gynecologist, validated with microscopy 
and culture of vaginal discharge. A sterile cotton swab was 
used for specimen collection from the VVC-confirmed 
patients and healthy women.
Yeast culture and identification 
The fungal cultures were prepared on BBL CHROMagar 
Candida medium (CCM)-contained plates by direct contact 
of swabs on the CCM surface. CCM is a chromogenic 
fungal specific medium that contains chloramphenicol to 
inhibit bacterial growth. In the case, different species of 
Candida, i.e. C. albicans, C. tropicalis and C. krusei were 
distinguished using CCM. Moreover, it has been shown 
that CCM can identify C. glabrata (8,9). The C. glabrata 
grows as dark pink colonies with pale edges on the 
CCM (8). Then, each group of homochromatic candida 
colonies was sub-cultured onto sabouraud dextrose agar 
(SDA) and investigated for their morphology under 
microscope. The identity of isolates was also confirmed 
by a polymerase chain reaction (PCR) detection method. 
The primer sequences used for PCR were as follows; 
forward: AAGAAGGCTGCCCGTTGTAATG and 
reverse: CACTTATCTAAACAACGGTGGC. The PCR 
reaction mixture and the protocol for programming of 
thermocycler machine were adapted from previous study 
(10).
Disc-diffusion antifungal susceptibility testing
Neo-Sensitabs™ fluconazole 25 μg discs (Rosco 
Diagnostica, Taastrup, Denmark) were used for disc-
diffusion in-vitro antifungal susceptibility testing (DAST) 
according to M44-A protocol (11). In brief, the yeast cell 
suspensions were prepared from all C. glabrata isolates 
then the suspensions were spread on the surface of 
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Mueller-Hinton agar medium (supplemented with 2% 
glucose) using cotton swabs. After incubation at 35 ± 2°C 
for 20-24 hours, the zones of inhibition around discs were 
measured using a ruler. The isolates were classified in one 
of following categories: resistant (R), susceptible dose-
dependent (SDD) and susceptible (S) groups, based on the 
definitions of M44-A protocol. A blank disc (without any 
drug) was used as negative control. The standard strains 
were used for reference and quality control purposes.
Broth microdilution antifungal susceptibility testing
The broth microdilution antifungal susceptibility 
testing (MAST) was carried out according to 
CLSI’s M27-A2 guideline. With preparing a broth 
medium (RPMI 1640 without sodium bicarbonate 
supplemented with 2% glucose), it was then buffered by 
morpholinepropanesulfonic acid (MOPS). Before being 
diluted with MOPS-buffered RMPI 1640 (MBR) broth 
medium, yeast suspensions were prepared using normal 
saline. A 0.5 McFarland standard was used as a reference 
to adjust the yeast concentration (103–5 x 103 CFU/mL). 
A two-fold stock solution of fluconazole was made at 
concentration of 128 µg/mL. Then, we prepared ten two-
fold concentrations of A-EtOH extract including 20, 18, 
16, 14, 12, 10, 8, 6, 4, 2 mg/mL using alcohol as a solvent. 
The final concentration of alcohol in the inoculated 
solution was limited to 5%. The yeast suspension and drug 
or herbal extract was inoculated in 96-well flat-bottomed 
plates and incubated at 35°C for 24 and 48 hours then 
visually evaluated. As defined, the minimum inhibitory 
concentration (MIC) of fluconazole is the lowest drug 
concentration that inhibits yeast growth by 50%. Also, 
the MIC of herbal extracts is defined as the lowest drug 
concentration that completely inhibits yeast growth.
Results
15.2% of VVC cases caused by Candida glabrata
Out of a total of 198 women with VVC and recurrent VVC, 
vaginal positive culture for C. glabrata was 16.2% (32 
patients). 14/198 (7.1%) of women were diagnosed with 
recurrent VVC while 184 (92.9%) of them were diagnosed 
with usual VVC. Among 32 women with a positive culture 
for C. glabrata, 28/184 (15.2%) did not experience a recent 
episode of C. glabrata-initiated VVC (CG-VVC) or 
experienced less than four episodes of CG-VVC during 1 
year. This means that out of a total of 32 women positive 
for C. glabrata, 28 women had experienced VVC while 
four experienced the recurrent VVC. Therefore, 15.2% 
of all VVC infections (28/184) caused by C. glabrata. Out 
of a total of 120 healthy volunteer women, 42 (35%) of 
women were colonized by different species of Candida. 
And of these women (42/120), eight of them (19%) were 
colonized by C. glabrata.
Fluconazole resistance was not seen in isolates obtained 
from healthy women but found in isolates from women 
with VVC
All C. glabrata isolates obtained from healthy women 
were identified as fluconazole-S. Only two isolates were 
identified as fluconazole-R among women with VVC. Two 
isolates (7.1%) obtained from patients with VVC were 
classified as fluconazole-R by both the DAST and MAST 
methods. However, the frequencies of fluconazole-S and 
SDD isolates were different by two methods. 24 (85.7%) 
and only 2 (7.1%) isolates were characterized as S and 
SDD, respectively by DAST method whereas 18 (64.3%) 
and 8 (28.6%) isolates were classified as S and SDD, 
respectively by MAST method (Table 1). All isolates in 
healthy group were identified as Flu-S by DAST method 
while only one strain was detected as Flu-SDD by MAST 
method. The MIC50 and MIC90 of fluconazole against 
isolates from healthy group were calculated as 2 and 4 µg/
mL, respectively (Table 1).
The A-EtOH extract could completely prevent growth of 
all fluconazole-R and fluconazole-non-R vaginal isolates 
of Candida glabrata
The A-EtOH extract showed fungicidal activity against C. 
glabrata isolates. The MIC90 of A-EtOH extract against 
C. glabrata isolates obtained from VVC patients was 3 
mg/mL. The MIC values of herb extract against either 
the azole-resistant or non-resistant isolates obtained from 
both evaluated groups (healthy women and women with 
VVC) were in a range between 1 to 3 mg/mL (Table 1). 
The MIC range of A-EtOH extract against fluconazole-
non-R isolates from patients with VVC was 1-3 mg/mL. 
Also, the MICs of A-EtOH extract against fluconazole-R 
isolates from patients with VVC were 3 mg/mL, being 
in the same MIC range of fluconazole-non-R isolates. 
Moreover, the MIC50 and MIC90 values calculated for 
isolates in the healthy group and VVC group were 2 and 3 
mg/mL, respectively (Table 1). In other words, the MIC50 
Table 1. MIC ranges, MIC50 and MIC90 of azoles and Allium jesdianum (aqueous-ethanol) extract and frequencies of azole-resistance 
in Candida glabrata isolates obtained from healthy individuals and patients with vulvovaginal candidiasis 
Participants Antifungals
MICa R
No. (%)
SDD
No. (%)
S
No. (%)50 (%) 90 (%) Range
VVC
Fluconazole 8 32 2-64 2 (7.1) 8 (28.6) 18 (64.3)
AJA 2 3 1-3 - - -
Healthy
Fluconazole 2 4 1-16 0 (0) 1 (12.5) 7 (87.5)
AJA 2 3 1-3 - - -
Abbreviations: VVC, patients with vulvovaginal candidiasis; AJA, Allium jesdianum aqueous-ethanol extract; MIC, minimum inhibitory concentration; 
No., number; R, resistant; SDD, susceptible dose-dependent; S, susceptible.
a MICs of fluconazole have been presented in µg/mL scale; MICs of AJA have been presented in mg/mL scale.
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and MIC90 values of herb extract against both groups of 
isolates obtained from VVC-patients and healthy women 
were the same (Table 1).
Discussion
The results of current study are consistent with previous 
studies reporting frequent isolation of C. glabrata from 
patients with VVC (2,12). C. glabrata is considered 
to be responsible for ~15.2% of VVC cases and the 
second prevalent cause of VVC after C. albicans. In our 
examinations, while 35.7% of isolates were classified as 
Flu-non-R (S or SDD) by MAST method, only 7.1% of C. 
glabrata isolates classified as the Flu-R. A previous study 
conducted in Iran showed that 10.8% of patients with 
vaginal infection were being diagnosed with an episode 
of VVC (13). Another similar research has also reported 
C. albicans as the most frequent Candida spp. in patients 
with VVC with frequency of 42.5%, and C. glabrata as the 
second most prevalent species with frequency of 21.9% 
(14). In our study, however C. glabrata was identified 
only in 19% of healthy women colonized by Candida spp, 
and out of a total of 120 healthy women, 42 (35%) were 
colonized by one species of Candida. In fact, 10-55% of 
healthy adult women were involved in asymptomatic 
colonization by one species of Candida (15). Another 
study reported that ~15% of women carrying Candida 
in the vagina were colonized by C. glabrata (16). 
Furthermore, in another study, C. albicans and C. glabrata 
were ~71% and ~19% of Candida spp. isolates obtained 
from patients with vulvovaginitis, respectively. They 
found that 3.7% of all Candida spp. isolates were resistant 
to fluconazole (Flu-R). The occurrence of Flu-resistance 
among C. glabrata isolates was higher than the others 
(2). In fact, no correlation was found between previous 
exposure to the over-the-counter azole antifungals and 
emergence of azole-resistant Candida spp. in patients with 
VVC (17). However, it has been known an inducible or 
acquired azole-resistance phenomenon among Candida 
spp. exposed continuously to azoles (18,19).
In our study, a higher number of Flu-S isolates were 
observed by the DAST method as compared to the MAST 
one. Therefore, out of a total 28 isolates obtained from 
VVC-patients, 8 isolates were classified as Flu-SDD by 
the MAST method, but only 2 isolates classified as Flu-
SDD by the DAST method. It has been shown that the disk 
diffusion method of antifungal susceptibility testing (AST) 
cannot appropriately distinguish between the susceptible 
and susceptible dose-dependent isolates of C. glabrata due 
to lack of sensitivity (20). The C. glabrata isolates tend to 
be categorized as susceptible to fluconazole in agar-based 
disk diffusion method of AST. However, the comparative 
evaluation of broth microdilution method of AST to disk 
diffusion method of AST showed a reliable detection 
of Flu-R isolates of C. glabrata by both methods (20). 
Furthermore, all isolates in healthy women were shown 
to be Flu-S by the DAST method with one as SDD by 
MAST. The absence of Flu-resistance among C. glabrata 
isolates from healthy women might be associated with the 
lack of pathogenicity and virulence of these strains and 
dominance of commensal bacteria in competence with 
Candida spp. to colonize the vagina.
In the current study, the antifungal effect of an endemic 
Iranian plant wildly-grown in northern, western and 
south-western regions of Iran; A. jesdianum (also known 
in Persian: Bon-e-Sorkh or Lizak, in Kurdish, Sourah 
Boneh) (21-23) was also examined. The fungicidal effect 
of the extract on both Flu-R and Flu-non-R isolates of 
C. glabrata was the same. According to these results, we 
could predicate that the herb extract are active against 
both fluconazole- resistant and susceptible isolates of C. 
glabrata, independent of the known mechanisms of azole 
resistance emerged in C. glabrata.
In this study, good antifungal activity of A-EtOH extract of 
AJ was achieved. The antifungal activity of Allium species 
extracts or essential oils has previously been reported (22). 
Our results are in agreement with similar studies evaluating 
antifungal activity of Allium species extracts on different 
fungal species. For instance, MIC90 of ethanolic extract 
of Allium ascalonicum against C. albicans was found to be 
8.65 mg/mL (24). In our examinations, MIC90 of A-EtOH 
extract against isolates collected from VVC-patients and 
healthy women was 3 mg/mL. Other studies found that 
the MFC of seven Allium species extracts against three 
filamentous fungi including Aspergillus niger, A. flavus and 
A. fumigatus was between 35-1536 µg/mL (25). In other 
study, the anti-C. albicans activity of 70% ethanolic extract 
of A. ascalonicum prepared by a maceration method at low 
temperature was reported (24).
Among a number of compounds present in the Allium 
spp., the thiosulfinate allicin has been known as the most 
abundant antimicrobial compound in garlic and most of 
the other Allium spp. Indeed, allicin and other members 
of organosulfur family of compounds have promising 
antimicrobial activities (26). Nonetheless, there is no 
allicin in fresh, raw garlic. Allicin is created by crushing 
the garlic. When cell lysis occurs, an endogenous enzyme 
called alliinase is released and converts the alliin to 
allicin (27). Allicin is a fragile compound sensitive to 
temperature and drying. It can be readily degraded during 
high-temperature drying or even at low temperatures 
(28). A solution of allicin prepared in water and ethanol 
could be preserved for longer periods of time compared to 
other solvents. Also, considerable amounts of allicin could 
be preserved in water solution than in ethanolic one (29). 
Conclusion
In conclusion, A. jesdianum showed good anti-C. glabrata 
activities so it is recommended as an alternative medicine 
and/or combination therapy for treating antifungal 
infections. It is worth noting that this study investigated 
the in vitro antifungal activity of herb extract only, 
therefore in vivo research must be performed to determine 
the cytotoxicity and side-effects of the extract. Also, 
further studies may be necessary to characterize the active 
ingredients and precise mode of anti-Candida action of A. 
jesdianum.
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